| |
| |
|
| Insider
Information: |
Stelzer Laurie |
| Relationship: |
Chief Financial Officer |
| City: |
San Diego |
| State: |
CA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
3 |
|
| Direct
Shares |
218,479 |
|
|
Indirect Shares
|
10,000 |
|
|
| Direct
Value |
$11,199,541 |
|
|
|
Indirect Value
|
$447,100 |
|
|
| Total
Shares |
228,479 |
|
|
| Total
Value |
$11,646,641 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
1
|
|
Stock
price went up :
|
0
|
1
|
| Stock
price went down : |
0
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
1.0
|
| Percentage
Gain/Loss : |
0.0%
|
 53.4%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Halozyme Therapeutics Inc |
HALO |
SVP, Chief Financial O... |
2020-02-22 |
116,167 |
2020-02-22 |
10,000 |
Premium* |
|
|
Arena Pharmaceuticals Inc |
ARNA |
EVP & Chief Financial ... |
2022-03-11 |
0 |
2021-03-01 |
0 |
Premium* |
|
|
Mirati Therapeutics, Inc. |
MRTX |
Chief Financial Officer |
2023-08-09 |
102,312 |
2022-06-01 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
37 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 2 of 2
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| HALO |
Halozyme Therapeutics Inc |
SVP, Chief Financial Officer |
• – – |
2020-02-03 |
4 |
D |
$19.21 |
$158,963 |
D/D |
(8,275) |
96,806 |
0 |
- |
|
| HALO |
Halozyme Therapeutics Inc |
SVP, Chief Financial Officer |
• – – |
2020-02-03 |
4 |
OE |
$0.00 |
$0 |
D/D |
23,119 |
105,081 |
0 |
- |
|
| HALO |
Halozyme Therapeutics Inc |
SVP, Chief Financial Officer |
• – – |
2020-02-12 |
4 |
D |
$20.00 |
$77,880 |
D/D |
(3,894) |
104,174 |
0 |
- |
|
| HALO |
Halozyme Therapeutics Inc |
SVP, Chief Financial Officer |
• – – |
2020-02-12 |
4 |
OE |
$0.00 |
$0 |
D/D |
11,262 |
108,068 |
0 |
- |
|
| HALO |
Halozyme Therapeutics Inc |
SVP, Chief Financial Officer |
• – – |
2020-02-14 |
4 |
D |
$21.10 |
$56,970 |
D/D |
(2,700) |
109,283 |
0 |
- |
|
| HALO |
Halozyme Therapeutics Inc |
SVP, Chief Financial Officer |
• – – |
2020-02-14 |
4 |
OE |
$0.00 |
$0 |
D/D |
7,809 |
111,983 |
0 |
- |
|
| HALO |
Halozyme Therapeutics Inc |
SVP, Chief Financial Officer |
• – – |
2020-02-22 |
4 |
D |
$21.83 |
$98,410 |
D/D |
(4,508) |
116,167 |
0 |
- |
|
| HALO |
Halozyme Therapeutics Inc |
SVP, Chief Financial Officer |
• – – |
2020-02-22 |
4 |
OE |
$0.00 |
$0 |
D/D |
11,392 |
120,675 |
0 |
- |
|
| MRTX |
Mirati Therapeutics, Inc. |
CFO |
• – – |
2022-06-01 |
4 |
A |
$0.00 |
$0 |
D/D |
57,798 |
57,798 |
0 |
- |
|
| MRTX |
Mirati Therapeutics, Inc. |
CFO |
• – – |
2023-01-20 |
4 |
A |
$0.00 |
$0 |
D/D |
26,864 |
84,662 |
0 |
- |
|
| MRTX |
Mirati Therapeutics, Inc. |
Chief Financial Officer |
• – – |
2023-06-02 |
4 |
S |
$37.06 |
$172,218 |
D/D |
(4,647) |
80,015 |
0 |
% |
|
| MRTX |
Mirati Therapeutics, Inc. |
Chief Financial Officer |
• – – |
2023-08-09 |
4 |
A |
$37.00 |
$824,989 |
D/D |
22,297 |
102,312 |
0 |
- |
|
37 Records found
|
|
Page 2 of 2 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
